Press release
Insmed Presents New Data Across Three Pillars at American Thoracic Society 2022 International Conference
—Retrospective Cohort Study Shows Significant Reductions in All-Cause and Respiratory Disease-Related Hospitalizations in the 12 Months Following ARIKAYCE®
About this update from Insmed Incorporated
[{"type":"text","content":"—Retrospective Cohort Study Shows Significant Reductions in All-Cause and Respiratory Disease-Related Hospitalizations in the 12 Months Following ARIKAYCE® (amikacin liposome inhalation suspension) Initiation in Real-World Settings—\n—Post-Hoc Analysis of Phase 2 WILLOW Study in Adult Patients with Non-Cystic Fibrosis Bronchiectasis Supports Favorable Benefit-Risk Profile of Brensocatib—\nBRIDGEWATER, N.J., May 17, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported data from seven presentations across three of its pillars—ARIKAYCE, brensocatib, and treprostinil palmitil inhalation powder (TPIP)—at the American Thoracic Society (ATS) 2022 International Conference.\n\"We were pleased to present a broad range of data at ATS from across our portfolio of programs, demonstrating our continued progress in addressing the needs of patients living with serious and rare diseases,\" said Martina Flammer, M.D., M.B.A, Chief Medical Officer of Insmed. \"In particular, we were excited to share the first real-world data for ARIKAYCE, which showed significant reductions in hospitalizations in the 12 months after ARIKAYCE was initiated. These findings provide important information to better understand the impact of ARIKAYCE in the treatment paradigm for refractory MAC lung disease.\"\nSummaries of these presentations are as follows:\nARIKAYCE \nPoster: \"Reduction in Hospitalizations Following Initiation of Amikacin Liposome Inhalation Suspension: A Retrospective Cohort Study of Patients in Real-world Settings\"\nData were presented from a noninterventional retrospective cohort study to assess changes in hospitalizations among patients initiating ARIKAYCE in the real-world setting. The study used the All-Payer Claims Database – including health insurance claims data from more than 300 million unique U.S. patients – to identify patients receiving ARIKAYCE from October 2018 to April 2020. An analysis of 331 patients who were treated with ARIKAYCE in the real-world setting showed the following key findings:\nA significant reduction in the proportion of patients with all-cause hospitalizations was observed after 6 months of ARIKAYCE treatment, from 35.9% in the 6 months immediately before ARIKAYCE initiation to 26.6% ...